FGD5-AS1

Summary

FGD5-AS1 (FGD5 antisense RNA 1, HGNC:40410) is a long non-coding RNA gene on chromosome 3p25.1.

At a glance

• Gene type: non-coding (lncRNA) — no protein product; not a drug target. Variant/disease associations are omitted (they would be positional, from an overlapping protein-coding gene).

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:40410
Approved symbol	FGD5-AS1
Name	FGD5 antisense RNA 1
Location	3p25.1
Locus type	RNA, long non-coding
Status	Approved
Ensembl gene	ENSG00000225733
Ensembl biotype	lncRNA
Entrez	100505641
RNAcentral	URS000075E0BE — lncRNA, 3805 nt, 1 organism(s)

Gene structure

Transcript identifiers

Ensembl transcripts: 10 — 10 lncRNA

ENST00000417835, ENST00000424349, ENST00000426200, ENST00000430166, ENST00000440079, ENST00000655923, ENST00000661022, ENST00000665449, ENST00000665738, ENST00000693748

RefSeq mRNA: 0 — MANE Select: None

Canonical transcript exons

ENST00000417835 — 2 exons

Exon	Start	End
ENSE00001613915	14944680	14946154
ENSE00001758038	14947739	14947893

Expression profiles

Bgee: expression breadth ubiquitous, 256 present calls, max score 99.18.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 34.1706 / max 225.9197, expressed in 1814 samples.

FANTOM5 promoters (7 alternative TSS)

Promoter ID	TPM avg	Samples expressed
41232	21.0508	1807
41234	5.8515	1651
41237	2.8018	1103
41238	2.2314	1037
41233	1.0131	589
41236	0.9397	525
41235	0.2824	155

Top tissues by expression

256 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
oviduct epithelium	UBERON:0004804	99.18	gold quality
upper arm skin	UBERON:0004263	98.12	gold quality
medial globus pallidus	UBERON:0002477	98.09	gold quality
adult organism	UBERON:0007023	97.99	gold quality
ventricular zone	UBERON:0003053	97.91	gold quality
globus pallidus	UBERON:0001875	97.85	gold quality
ganglionic eminence	UBERON:0004023	97.73	gold quality
cortical plate	UBERON:0005343	97.72	gold quality
seminal vesicle	UBERON:0000998	97.58	gold quality
subthalamic nucleus	UBERON:0001906	97.11	gold quality
ileal mucosa	UBERON:0000331	97.10	gold quality
synovial joint	UBERON:0002217	97.07	gold quality
C1 segment of cervical spinal cord	UBERON:0006469	97.07	gold quality
spinal cord	UBERON:0002240	97.03	gold quality
bronchial epithelial cell	CL:0002328	97.01	gold quality
lateral globus pallidus	UBERON:0002476	96.94	gold quality
caput epididymis	UBERON:0004358	96.84	gold quality
bronchus	UBERON:0002185	96.83	gold quality
adrenal tissue	UBERON:0018303	96.82	gold quality
jejunal mucosa	UBERON:0000399	96.75	gold quality
germinal epithelium of ovary	UBERON:0001304	96.73	gold quality
rectum	UBERON:0001052	96.51	gold quality
calcaneal tendon	UBERON:0003701	96.50	gold quality
layer of synovial tissue	UBERON:0007616	96.50	gold quality
skin of hip	UBERON:0001554	96.48	gold quality
smooth muscle tissue	UBERON:0001135	96.46	gold quality
jejunum	UBERON:0002115	96.46	gold quality
popliteal artery	UBERON:0002250	96.39	gold quality
tibial artery	UBERON:0007610	96.39	gold quality
medulla oblongata	UBERON:0001896	96.37	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	no	0.00

Regulation

Is transcription factor: no

Literature-anchored findings (GeneRIF, showing 31)

• The inhibiting effects of FGD5-AS1 knockdown on colorectal cancer (CRC) cell proliferation, migration, and invasion, and the promoting effects on CRC cell apoptosis could be revived by miR-302e suppression or CDCA7 upregulation. (PMID:31332696)
• FGD5-AS1 regulates oral squamous cell carcinoma via competitively binding to miR-520b against USP21. (PMID:31899825)
• Long non-coding RNA FGD5-AS1 promotes non-small cell lung cancer cell proliferation through sponging hsa-miR-107 to up-regulate FGFRL1. (PMID:31919528)
• Elevation of FGD5-AS1 contributes to cell progression by improving cisplatin resistance against non-small cell lung cancer cells through regulating miR-140-5p/WEE1 axis. (PMID:32534055)
• FGD5-AS1 facilitates glioblastoma progression by activation of Wnt/beta-catenin signaling via regulating miR-129-5p/HNRNPK axis. (PMID:32585241)
• LncRNA FGD5-AS1 promotes tumor growth by regulating MCL1 via sponging miR-153-3p in oral cancer. (PMID:32675387)
• LncRNA FGD5-AS1/miR-5590-3p axis facilitates the proliferation and metastasis of renal cell carcinoma through ERK/AKT signalling. (PMID:32964964)
• Expression of lncRNA FGD5-AS1 correlates with poor prognosis in melanoma patients. (PMID:32997827)
• lncRNA FGD5 antisense RNA 1 upregulates RORA to suppress hypoxic injury of human cardiomyocyte cells by inhibiting oxidative stress and apoptosis via miR195. (PMID:33174051)
• FGD5AS1 promotes cisplatin resistance of human lung adenocarcinoma cell via the miR1425p/PDL1 axis. (PMID:33416094)
• Long non-coding RNA FGD5-AS1 is an inducer of cisplatin chemoresistance in gastric cancer cells by sponging miR-195. (PMID:33687911)
• LncRNA FGD5-AS1 accelerates cell proliferation in pancreatic cancer by regulating miR-520a-3p/KIAA1522 axis. (PMID:33794727)
• FGD5-AS1 Inhibits Osteoarthritis Development by Modulating miR-302d-3p/TGFBR2 Axis. (PMID:33834880)
• LncRNA FGD5-AS1 promotes the malignant phenotypes of ovarian cancer cells via targeting miR-142-5p. (PMID:33974163)
• The LncRNA FGD5-AS1/miR-497-5p axis regulates septin 2 (SEPT2) to accelerate cancer progression and increase cisplatin-resistance in laryngeal squamous cell carcinoma. (PMID:34003510)
• Upregulation of Long Noncoding RNA FGD5-AS1 Ameliorates Myocardial Ischemia/Reperfusion Injury via MicroRNA-106a-5p and MicroRNA-106b-5p. (PMID:34173804)
• Long non-coding RNA FGD5-AS1 contributes to cisplatin resistance in hepatocellular carcinoma via sponging microRNA-153-3p by upregulating Twinfilin Actin Binding Protein 1 (TWF1). (PMID:34519634)
• Long Non-Coding RNA FGD5-AS1 Induced by Chlamydia trachomatis Infection Inhibits Apoptosis via Wnt/beta-Catenin Signaling Pathway. (PMID:34568091)
• Activation of FGD5-AS1 Promotes Progression of Cervical Cancer through Regulating BST2 to Inhibit Macrophage M1 Polarization. (PMID:34692852)
• LncRNA FGD5-AS1 functions as an oncogene to upregulate GTPBP4 expression by sponging miR-873-5p in hepatocellular carcinoma. (PMID:34783233)
• FGD5AS1 is an oncogenic lncRNA in pancreatic cancer and regulates the Wnt/betacatenin signaling pathway via miR577. (PMID:34821374)
• The role of long non-coding RNA FGD5-AS1 in cancer. (PMID:35475392)
• Exosome-derived FGD5-AS1 promotes tumor-associated macrophage M2 polarization-mediated pancreatic cancer cell proliferation and metastasis. (PMID:35718269)
• EBF1-mediated up-regulation of lncRNA FGD5-AS1 facilitates osteosarcoma progression by regulating miR-124-3p/G3BP2 axis as a ceRNA. (PMID:35761386)
• LncRNA FGD5-AS1 drives the malignant development of gastric cancer by negatively interacting with FZD3. (PMID:35848483)
• LncRNA FGD5-AS1 potentiates autophagy-associated doxorubicin resistance by regulating the miR-154-5p/WNT5A axis in osteosarcoma. (PMID:36041209)
• lncRNA FGD5-AS1 acts as a ceRNA to regulate lipopolysaccharide-induced injury via the miR-223-3p-3p/GAS5 axis in cardiomyocytes. (PMID:36445031)
• Long noncoding RNA FGD5-AS1 alleviates childhood IgA nephropathy by targeting PTEN-mediated JNK/c-Jun signaling pathway via miR-196b-5p. (PMID:36641136)
• Abnormal expression of long non-coding RNA FGD5-AS1 affects the development of ovarian cancer through regulating miR-107/RBBP6 axis. (PMID:37322627)
• Long non-coding RNA FGD5 antisense RNA 1 targets Baculovirus inhibitor 5 via microRNA-497-5p to alleviate calcific aortic valve disease. (PMID:37355887)
• LncRNA FGD5-AS1 Alleviates Inflammation in Allergic Rhinitis through the miR-223-3p/COX11 Axis. (PMID:38071964)

Cross-species orthologs

0 orthologs

Protein

Non-coding RNA — no protein product; not a drug target.

Function

No curated pathway, Gene-Ontology, or interaction data.

Disease & clinical

No curated disease, variant, or cancer-driver associations.

Drugs & pharmacology

No drug or pharmacology data — not an established drug target.